argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update $1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year ‑ over ‑ year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS

#ARGX argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

www.stocktitan.net/news/ARGX/argenx-reports...

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis Study met primary endpoint (p-value = 0.012) First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label

#ARGX argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis

www.stocktitan.net/news/ARGX/argenx-announc...

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG January 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for

#ARGX argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

www.stocktitan.net/news/ARGX/argenx-announc...

argenx Highlights 2026 Strategic Priorities Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end of 2026

#ARGX argenx Highlights 2026 Strategic Priorities

www.stocktitan.net/news/ARGX/argenx-highlig...

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease 15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous

#ARGX argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

www.stocktitan.net/news/ARGX/argenx-provide...

Good Morning!

Futures flat

#ARGX d/g Peer Perform @ Wolfe
#CLSK u/g Overweight @ JPM
#PRIM int Sell @ GS pt $117
#MRKT u/g Overweight @ WFC pt $125
#SNOW pt raised $300 from $270 @ Jefferies

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update $1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study readouts expected in 2026 from leading immunology pipeline

#ARGX argenx Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/ARGX/argenx-reports...

argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activity Final ADAPT SC+ results show ~60% of VYVGART gMG patients achieved minimal symptom expression (MSE), with 88% sustaining MSE

#ARGX argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients

www.stocktitan.net/news/ARGX/argenx-present...

argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session argenx (NASDAQ:ARGX) will present more than 40 abstracts at the 2025 AANEM Annual Meeting and MGFA Scientific Session (Oct 29–Nov 1, 2025) covering VYVGART (IV and SC/Hytrulo) and pipeline candidate empasiprubart.Key highlights include pivotal ADAPT SERON results showing clinically meaningful improvements with VYVGART in anti-AChR antibody–negative generalized myasthenia gravis across triple negative, MuSK, and LRP4 subtypes; interim ADAPT Jr data in juvenile gMG; long-term and real-world evidence for sustained benefit; and Phase 2/3 programs for empasiprubart in CIDP and MMN (EMVIGORATE, EMNERGIZE, EMPASSION).

#ARGX argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session

www.stocktitan.net/news/ARGX/argenx-to-high...

NEWS: ( NASDAQ: #ARGX ) argenx to Present at Upcoming Investor Conferences

Breakthrough: VYVGART Shows First-Ever Success Across All Seronegative gMG Subtypes in Phase 3 Trial argenx's VYVGART achieves statistical significance (p=0.0068) in ADAPT SERON study for seronegative gMG patients. FDA submission planned for 2025. First study showing efficacy across MuSK+, LRP4+, triple seronegative subtypes.

#ARGX argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

www.stocktitan.net/news/ARGX/argenx-announc...

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update argenx (NASDAQ:ARGX) reported strong Q2 2025 financial results, with global product net sales reaching $949 million, representing 97% year-over-year growth. The company achieved $245 million in quarterly profit, with earnings per share of $4.02.VYVGART SC launch in CIDP has gained momentum with over 2,500 patients on treatment globally. The company announced positive proof-of-concept data for ARGX-119 in CMS, advancing to a registrational study. argenx maintains its Vision 2030 goal of treating 50,000 patients globally, securing 10 labeled indications, and advancing five pipeline candidates to Phase 3.The company's R&D and SG&A guidance remains at $2.5 billion, with six registrational and six proof-of-concept readouts expected by end of 2026.

#ARGX argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

www.stocktitan.net/news/ARGX/argenx-reports...

argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes argenx SE (Nasdaq: ARGX) announced plans to advance ARGX-119, their first-in-class agonist antibody targeting muscle-specific kinase (MuSK), to a registrational study for congenital myasthenic syndromes (CMS) following positive Phase 1b results.The Phase 1b multicenter, randomized, double-blinded, placebo-controlled trial demonstrated a favorable safety and tolerability profile for ARGX-119. The study showed consistent improvements in DOK7-CMS patients across multiple efficacy measures throughout the 12-week study period, including Six-Minute Walk Test, Quantitative Myasthenia Gravis score, and Myasthenia Gravis Activities of Daily Living score.The trial design included a 4:1 randomization to ARGX-119 or placebo, with an 11-month duration comprising screening, treatment, and follow-up periods. ARGX-119 represents the sixth successful molecule developed through argenx's Immunology Innovation Program (IIP), validating their collaborative discovery model.

#ARGX argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes

www.stocktitan.net/news/ARGX/argenx-advance...

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy argenx (ARGX) has received European Commission approval for VYVGART SC (efgartigimod alfa) as a monotherapy for treating adult CIDP patients after prior corticosteroid or immunoglobulin treatment. This marks the first novel treatment mechanism for CIDP in over 30 years. The approval is based on the ADHERE trial, where 66.5% of patients showed clinical improvement and demonstrated a 61% reduction in relapse risk versus placebo. VYVGART SC, available as a vial or prefilled syringe, can be self-administered weekly with potential adjustment to bi-weekly dosing. The treatment specifically targets the neonatal Fc receptor (FcRn) and showed consistent safety results with previous studies. This approval applies to all 27 EU Member States plus Iceland, Liechtenstein, and Norway, representing a significant advancement for CIDP patients who often experience severe mobility issues and disability.

#ARGX argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

www.stocktitan.net/news/ARGX/argenx-announc...

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease argenx (ARGX) presented positive Phase 2 results for efgartigimod in treating myositis and Sjogren's disease at EULAR 2025. In the ALKIVIA myositis study, efgartigimod showed significant improvement in muscle strength with a mean Total Improvement Score of 50.45 vs 35.65 for placebo (P=0.0004). 79% of treated patients achieved moderate improvement and 34% achieved major improvement. For Sjogren's disease, the RHO study showed 45.5% of efgartigimod patients achieved improved outcomes vs 11.1% for placebo. The drug demonstrated sustained IgG reduction of ~60% and decreased disease-associated antibodies. The FDA granted Fast Track designation for efgartigimod in primary Sjogren's disease. Both studies showed favorable safety profiles, and Phase 3 trials (ALKIVIA and UNITY) are ongoing.

#ARGX argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease

www.stocktitan.net/news/ARGX/argenx-present...

argenx Reports First Quarter 2025 Financial Results and Provides Business Update $790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC (vial and pre-filled syringe) in EU Management to host conference call today at

#ARGX argenx Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/ARGX/argenx-reports...

$IPHA BULLRUN Chart + Positive News with #Sanofi Deal. 300% = $8.00 PT

#SNY #SANOFI
#VRTX #REGN
#ARGX #ALNY

argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP argenx (ARGX) presented significant data at the AAN 2025 Annual Meeting, highlighting the sustained efficacy of VYVGART in treating generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP).The ADAPT-NXT study showed that 75% of gMG patients achieved sustained improvement, with 56.5% reaching minimal symptom expression. The ADHERE+ data demonstrated VYVGART Hytrulo's long-term efficacy in CIDP patients, with 50% of relapsed patients restabilizing by week 4.The company also revealed promising first-in-human data for ARGX-119, their third clinical candidate for neuromuscular junction disorders. Additionally, argenx is expanding VYVGART's applications through two Phase 3 studies: ADAPT-SERON for seronegative gMG and ADAPT-OCULUS for ocular MG.

#ARGX argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP

www.stocktitan.net/news/ARGX/argenx-highlig...

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting argenx (ARGX) presented clinical trial and real-world data for VYVGART® and VYVGART® Hytrulo at the American Academy of Neurology Annual Meeting 2025. The data demonstrates consistent, favorable safety profiles and sustained clinical improvements for patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP).Key highlights include:ADAPT-NXT data showed sustained clinical improvements through 126 weeks with biweekly or three-week dosingADAPT-SC+ analyses demonstrated consistent safety and sustained efficacy through nine treatment cyclesComparative effectiveness study revealed VYVGART shows more favorable benefit-risk profile among immunomodulatory therapiesADHERE+ interim results support long-term efficacy and functional improvement in CIDP patientsPhase 4 trial investigating transition from IVIg to VYVGART Hytrulo within one week

#ARGX argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

www.stocktitan.net/news/ARGX/argenx-highlig...

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update argenx reported strong financial results for 2024, with global product net sales reaching $737 million in Q4 and $2.2 billion for the full year. The company received positive CHMP recommendation for VYVGART pre-filled syringe for gMG in the EU, with FDA decisions expected by April 10, 2025.The company surpassed 10,000 patients across three indications with VYVGART and expects to become profitable in 2025. argenx is advancing its Vision 2030 strategy, aiming to treat 50,000 patients globally, secure 10 labeled indications, and advance five pipeline candidates to Phase 3.Key developments include 20 ongoing clinical studies (10 Phase 3 and 10 Phase 2) across their pipeline in 2025. The company recognized a one-time tax benefit of $725 million related to previously unrecognized deferred tax assets. Full-year 2024 profit was $833 million, compared to a loss of $295 million in 2023.

#ARGX argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

www.stocktitan.net/news/ARGX/argenx-reports...

Earnings to watch
#DPZ #HIMS #KBR #TCOM #ZM #BNS #CPNG #FANG #CZR #HD #FSLR #IMOS #INTU #KDP #LCID #PLNT #WDAY #WK #AAP #A #LOW #AI #TJX #AMBA #CRM #EBAY #IONQ #MORN #NTNX #NVDA #PSTG #SNOW #SNPS #URBN #ACIW #ADSK #ARGX #CM #DUOL #EVERG #ESTC #NCLH #HPQ #RY #MNST #SATS #NTAP #SJM #SOUN #TD #VERX

argenx Hits $2.2B in 2024 Sales, Plans Major Pipeline Expansion with 20 Clinical Studies argenx reports strong Q4 with $737M in sales, targets profitability in 2025 with ambitious clinical program and VYVGART expansion. Cash position remains robust at $3.4B.

#ARGX argenx Highlights 2025 Strategic Priorities

www.stocktitan.net/news/ARGX/argenx-highlig...

#ARGX argenx to Present at Upcoming Investor Conferences

www.stocktitan.net/news/ARGX/argenx-to-pres...

#ARGX argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

www.stocktitan.net/news/ARGX/argenx-advance...